TP508 (Chrysalin): Research Guide & Chemical Profile

TP508, marketed under the research name Chrysalin, is a synthetic 23-amino-acid peptide corresponding to the receptor binding domain of human thrombin (amino acids 508-530 of prothrombin). Unlike full-length thrombin, TP508 has no enzymatic (serine protease) activity and does not activate the coagulation cascade. Instead, it functions as a non-proteolytic activator of thrombin receptors on the surface of endothelial cells, osteoblasts, and fibroblasts, triggering downstream signaling cascades involved in tissue repair, angiogenesis, and bone formation. TP508 received FDA orphan drug designation for the treatment of distal radius fractures, making it one of the few peptides to achieve this regulatory milestone.

TP508 has the sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val with a molecular weight of approximately 2,308 Da. The peptide contains a single cysteine residue at position 14, which can form intermolecular disulfide bonds under oxidizing conditions. For research applications, the reduced monomeric form is preferred and should be maintained using inert gas headspace or low concentrations of reducing agents such as TCEP during storage.

The sequence includes an Arg-Gly-Asp (RGD) motif at positions 10-12, which is a well-characterized integrin-binding sequence. However, structure-activity studies have shown that the RGD motif alone does not account for the full biological activity of TP508 — the flanking residues and overall peptide conformation contribute to receptor selectivity that distinguishes TP508 from generic RGD peptides.

Thrombin is a multifunctional serine protease that, beyond its role in coagulation, activates protease-activated receptors (PARs) on cell surfaces to promote tissue repair processes. The receptor binding domain (residues 508-530) was identified as the minimal region required for non-proteolytic receptor engagement. TP508 binds to a subset of thrombin-responsive receptors — particularly a non-PAR thrombin binding site identified on endothelial cells — without requiring the catalytic triad (His-57, Asp-102, Ser-195) that defines thrombin enzymatic activity.

This mechanism allows TP508 to stimulate tissue repair signaling without the thrombotic risks associated with full-length thrombin. In binding competition assays, TP508 displaces radiolabeled thrombin from endothelial cell surfaces with an IC50 of approximately 10 nM, indicating high-affinity receptor interaction.

TP508 has been most extensively studied in bone fracture healing models. In a rabbit femoral osteotomy model, a single injection of TP508 (100 ug in a calcium sulfate carrier) into the fracture site accelerated radiographic union by 40% compared to carrier alone. Micro-CT analysis at 6 weeks revealed increased callus bone mineral density (BMD) and enhanced bridging callus formation. Biomechanical testing showed that TP508-treated fractures achieved 70% of intact bone strength at 6 weeks versus 45% for controls.

In a rat closed femoral fracture model, TP508 increased the rate of endochondral ossification and accelerated the transition from cartilaginous to bony callus. Histomorphometric analysis demonstrated increased osteoblast surface area, elevated mineral apposition rate, and accelerated remodeling of woven bone to lamellar bone. Gene expression profiling of fracture callus tissue showed upregulation of osteogenic markers including Runx2, osteocalcin, and bone sialoprotein following TP508 treatment.

A key mechanism underlying the bone-healing effects of TP508 is its potent pro-angiogenic activity. In endothelial cell tube formation assays, TP508 at 1-10 uM stimulated capillary-like network formation comparable to VEGF at 10 ng/mL. The angiogenic mechanism involves upregulation of VEGF expression in osteoblasts and direct stimulation of endothelial cell proliferation and migration through thrombin receptor-mediated activation of the MAPK/ERK pathway.

In a rat ischemic hindlimb model, intramuscular injection of TP508 increased capillary density by 65% at 14 days post-ischemia compared to saline controls, as quantified by CD31 immunohistochemistry. Laser Doppler perfusion imaging confirmed functional blood flow restoration, with TP508-treated limbs achieving 85% of contralateral normal perfusion versus 55% for controls. These findings support the concept that TP508 promotes functional revascularization rather than merely increasing vessel number.

Beyond bone, TP508 has shown efficacy in dermal wound healing models. In diabetic (db/db) mice, topical application of TP508 (1 ug per wound) accelerated wound closure by 35% at day 10 compared to vehicle. Wound tensile strength at day 21 was increased by 50% in TP508-treated wounds. The mechanism involves increased granulation tissue formation, enhanced collagen deposition (primarily type I collagen), and improved neovascularization of the wound bed.

In a porcine full-thickness wound model — considered the gold standard for translational wound research due to anatomical similarity to human skin — TP508 treatment reduced time to complete re-epithelialization by approximately 4 days compared to controls. Dermal remodeling at 60 days post-wounding showed improved collagen fiber organization and reduced scar width in TP508-treated wounds.

TP508 received FDA orphan drug designation for the treatment of distal radius fractures, based on preclinical evidence demonstrating accelerated fracture healing. Orphan drug designation provides regulatory incentives including tax credits for clinical research, waiver of FDA application fees, and 7 years of market exclusivity upon approval. A Phase 1/2 clinical trial evaluated TP508 injected into acute distal radius fracture sites at the time of closed reduction, with radiographic healing assessed by serial X-rays and CT scans.

The clinical data showed a trend toward accelerated radiographic union in TP508-treated fractures, with the peptide demonstrating an acceptable safety profile. No serious adverse events were attributed to TP508 treatment. However, the development program has not progressed to Phase 3 trials as of the current literature, and the compound remains primarily a research tool for studying thrombin receptor-mediated tissue repair mechanisms.

Research-grade TP508 is characterized by HPLC purity of 95% or higher, confirmed by reversed-phase C18 chromatography. Mass spectrometry should confirm the [M+H]+ ion at m/z 2,309. The oxidation state of Cys-14 must be monitored, as disulfide-linked dimers represent the primary degradation product. Certificates of Analysis should include amino acid analysis, mass spectrometry data, free thiol content (Ellman assay), and endotoxin testing for in vivo applications.

• Sheller MR et al. (2004). Repair of rabbit segmental defects with TP508. J Orthop Res, 22(5):1094-1099.
• Li G et al. (2005). TP508 accelerates fracture repair. J Orthop Res, 23(3):671-679.
• Stiernberg J et al. (2000). TP508 stimulates angiogenesis. Angiogenesis, 3(3):261-270.
• Norfleet AM et al. (2000). Thrombin peptide TP508 accelerates wound closure. Wound Repair Regen, 8(6):517-525.
• Carney DH et al. (1992). Enhancement of incisional wound healing by thrombin peptide TP508. J Clin Invest, 89(5):1469-1477.
• Wang H et al. (2005). TP508 promotes bone formation via thrombin receptor signaling. Bone, 36(Suppl 1):S243.
• Hedberg EL et al. (2005). Controlled release of TP508 from biodegradable scaffolds. J Biomed Mater Res A, 72(4):343-353.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: B7-33: Research Guide & Chemical Profile → https://www.chemverify.com/learn/b7-33-research-guide-chemical-profile
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism